Navco Pharmaceuticals Inc.
NAV.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -95.38% | -96.43% | -96.73% | -46.05% | -51.45% |
| Depreciation & Amortization | 100.00% | -97.09% | -95.97% | -144.98% | -105.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -95.37% | -96.44% | -96.71% | -51.26% | -53.08% |
| Operating Income | 95.37% | 96.44% | 96.71% | 51.26% | 53.08% |
| Income Before Tax | 93.31% | 95.00% | 95.50% | -280.45% | 60.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.31% | 95.00% | 95.50% | -280.45% | 60.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.31% | 95.00% | 95.50% | -280.45% | 60.12% |
| EBIT | 95.37% | 96.44% | 96.71% | 51.26% | 53.08% |
| EBITDA | 98.33% | 98.34% | 98.19% | 50.21% | 53.92% |
| EPS Basic | 93.53% | 95.31% | 96.27% | -198.32% | 70.74% |
| Normalized Basic EPS | 93.67% | 95.54% | 95.77% | 61.76% | 64.09% |
| EPS Diluted | 93.53% | 95.31% | 96.27% | -198.32% | 70.74% |
| Normalized Diluted EPS | 93.67% | 95.54% | 95.77% | 61.76% | 64.09% |
| Average Basic Shares Outstanding | 0.71% | 2.22% | 10.49% | 20.26% | 29.69% |
| Average Diluted Shares Outstanding | 0.71% | 2.22% | 10.49% | 20.26% | 29.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |